Provident Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Provident Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-726,333	Closed	-$24M	–	57
2019 Q2	$24M	Buy	726,333 +88,099	+14%	+$3.02M	3.56%	16
2019 Q1	$22.4M	Buy	638,234 +74,730	+13%	+$2.78M	3.67%	16
2018 Q4	$18.7M	Sell	563,504 -26,765	-5%	-$1.15M	3.34%	16
2018 Q3	$29.7M	Buy	590,269 +47,075	+9%	+$2.32M	4.23%	14
2018 Q2	$32.5M	Buy	543,194 +3,658	+0.7%	+$189K	4.61%	7
2018 Q1	$24.7M	Buy	+539,536	New	+$22.5M	3.9%	15

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Provident Investment Management's SUPN Position: Q3 2019 in Review

Provident Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2019, closing a stake of 726,333 shares — an estimated $24M sold.

Provident Investment Management first reported a position in SUPN in Q1 2018 and held it in 6 quarters. The position peaked at $32.5M in Q2 2018. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

Provident Investment Management reported no remaining Supernus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Provident Investment Management sold 726,333 Supernus Pharmaceuticals shares in Q3 2019, an estimated $24M.
Provident Investment Management first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 6 quarters.
Provident Investment Management's Supernus Pharmaceuticals position peaked at $32.5M in Q2 2018.
243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Provident Investment Management's 13F filing for Q3 2019, filed 6 Nov 2019.